K-V Pharma (KV-A)(KV.A) Unit Aims to Reduce Price of Makena

K-V Pharmaceutical Company (NYSE: KV-A)(NYSE: KV.A) subsidiary, Ther-Rx Corp., announced initiatives to reduce the price on Makena.

The initiatives include:

• Reduced the list price of Makena by nearly 55 percent, to $690 per injection;
  
  
• Will offer supplemental rebates that, in conjunction with the list price reduction and the standard Medicaid rebate of 23.1 percent, will result in a substantially reduced cost per injection for state Medicaid agencies compared to list price. This will help ensure that every woman who is prescribed Makena – regardless of her ability to pay – has the comfort of knowing a medication that has been rigorously reviewed by FDA for safety and efficacy is available to her;
  
  
• Capped the costs for a full course of therapy to a maximum of three vials (15 injections) for contracted health insurance plans and state Medicaid agencies; and
  
  
• Expanded the Company's patient assistance program for patients who are prescribed this important medication by removing income caps to qualify for financial assistance. 85 percent of patients will pay $20 or less per injection for FDA-approved Makena, and patients whose financial need is greatest would receive FDA-approved Makena at no out-of-pocket cost.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
• loanDepot receives NYSE non-compliance notice over stock price
• enVVeno Medical (NVNO) files $100M mixed shelf